| Stage (INSS) | Stage 4S | 3 | 60.0 | 2 | 40.0 | 0 | 0 | <0.05 (Sig) |
| Stage 1 | 4 | 100.0 | 0 | 0 | 0 | 0 | ||
| Stage 2 | 1 | 100.0 | 0 | 0 | 0 | 0 | ||
| Stage 3 | 0 | 0 | 12 | 92.3 | 1 | 7.7 | ||
| Stage 4 | 0 | 0 | 3 | 15.8 | 16 | 84.2 | ||
| MYCN gene Status | Amplified | 0 | 0 | 0 | .0 | 10 | 100.0 | <0.05 (Sig) |
| Not Amplified | 7 | 26.9 | 15 | 57.7 | 4 | 15.4 | ||
| Not done | 1 | 16.7 | 2 | 33.3 | 3 | 50.0 | ||
| INPC | Favorable Histology | 8 | 30.8 | 14 | 53.8 | 4 | 15.4 | <0.05 (Sig) |
| Unfavorable Histology | 0 | 0 | 2 | 14.3 | 12 | 85.7 | ||
| Unknown | 0 | 0 | 1 | 50.0 | 1 | 50.0 | ||
| Outcome | Survived | 8 | 23.5 | 15 | 44.1 | 11 | 32.4 | >0.05 (NS) |
| Died | 0 | 0 | 2 | 25.0 | 6 | 75.0 | ||
| Overall Survival (month) | Median (min, max) | 29.5 (8, 96) | 15.0 (5, 86) | 14.0 (1, 93) | >0.05 (NS) | |||
| Disease Free Survival (month) | Median (min, max) | 28.0 (5, 92) | 12.0 (0, 86) | 12.0 (1, 87) | >0.05 (NS) | |||